| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | ||
|---|---|---|---|---|---|---|
Grant revenue | ||||||
- | - | - | - | 522 | ||
Operating expenses | ||||||
Research and development | ||||||
89,002 | 70,683 | 53,881 | 25,161 | 12,730 | ||
General and administrative | ||||||
40,039 | 18,603 | 7,087 | 5,230 | 3,216 | ||
Total operating expenses | ||||||
129,041 | 89,286 | 60,968 | 30,391 | 15,946 | ||
Operating loss | ||||||
-129,041 | -89,286 | -60,968 | -30,391 | -15,424 | ||
Other income (expense) | ||||||
Other income | ||||||
6,594 | 3,998 | 888 | 182 | 18 | ||
Change in fair value in warrant liability and other liabilities | ||||||
- | - | 41 | 82 | 85 | ||
Change in fair value of Series B purchase option liability | ||||||
- | - | - | - | -4,772 | ||
Total other income, net | ||||||
6,594 | 3,998 | 847 | 100 | -4,839 | ||
Net loss | ||||||
-122,447 | -85,288 | -60,121 | -30,291 | -20,263 | ||
Accretion of redeemable convertible preferred stock | ||||||
- | - | 4,757 | 4,405 | 1,427 | ||
Net loss attributable to common stockholders | ||||||
-122,447 | -85,288 | -64,878 | -34,696 | -21,690 | ||
Net loss per share attributable to common stockholders, basic and diluted | ||||||
-3.27 | -2.56 | -3.57 | -23.33 | -16.13 | ||
Weighted average common shares outstanding, basic and diluted | ||||||
37,499 | 33,316 | 18,197 | 1,486 | 1,344 | ||